Event
Faro live at DPHARM 2026: Agentic AI as a Design Partner
8 September, 2026
Faro Heads to DPHARM 2026: Two Sessions on Structured Protocols and Agentic AI
Faro is heading to DPHARM: Disruptive Innovations to Modernize Clinical Trials 2026, where our team will take the stage twice to talk about what it actually takes to make AI reliable in clinical development: structured data. Below is what to expect from each session, and how to find us while you're there.
Session 1: From Protocol to Schedule of Activities: Agentic AI as a Design Partner
Tuesday, September 15 | 11:45 AM Eastern
Faro CEO and Co-Founder Scott Chetham will present on how agentic AI can support one of the most consequential parts of protocol design: the Schedule of Activities.
The challenge. Sponsor teams are being asked to deliver more studies with fewer resources, and the Schedule of Activities is often where that pressure shows up first. Scott's session looks at how agentic AI can act as a design partner, translating protocol intent into a structured SoA and helping teams surface design tradeoffs earlier, before they become amendments.
Why the SoA matters. The Schedule of Activities sits at the intersection of scientific intent and operational execution. It shapes site workload, patient burden, cost, timelines, and everything downstream in study build. Small design decisions made here ripple across the entire trial, which makes it a high-leverage place for sponsors to scale their design work.
How agentic AI helps. Rather than summarizing a document, agentic AI can reason across the components that actually determine an SoA: objectives, endpoints, assessments, visit logic, study constraints, and operational standards. That reasoning is what allows lean clinical teams to generate and review a structured SoA directly from protocol intent, instead of building it manually from scratch.
Responsible deployment. None of this works in a regulated environment without the right guardrails. Scott's session addresses what sponsor teams need to trust AI-generated design outputs: human review, traceability, governance, validation, and clear controls at every step.
Session 2: Streamlining Clinical Data Flow from Study Design to Submission
Track 5D: Modernizing Clinical Data Management & Digital Innovation Fairfax | 2:45–3:20 PM
Scott will also join a panel exploring how ICH M11 and structured protocol frameworks can change the way clinical data moves through the trial lifecycle, from design, to build, to execution, to regulatory submission.
He'll be joined by:
- Bill Illis — Global Head, Collaboration and Technology Strategy, Novartis (moderator)
- Rachel Zebo — Head of Reference Data Management, Merck
- Aaron Zhang, PhD — Sr. Manager, Global Development Advanced Informatics, Regeneron
- Charlie Paterson — Partner, Clinical Development, PA Consulting
Together, the panel will cover:
- How ICH M11 enables earlier alignment between protocol design, study build, and downstream data standards
- The role of clinical data standards in improving traceability from protocol to submission
- How structured, reusable protocol content can cut manual rework and accelerate timelines
- Lessons learned from operationalizing structured protocols across teams and systems
This is the shift Faro is built for: moving the industry from static documents to structured, machine-readable protocols that carry their intelligence all the way to submission.
Visit Us at Booth #532
Stop by to see a live demo of Faro's digital protocol platform and talk with our team about what structured data unlocks for AI in clinical development.
Interested in setting up a meeting at DPHARM? Reach out to Vivian DeWoskin or contact sales@farohealth.com.
Related updates & insights
